Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

INFORMS study investigators

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background no treatments have been approved for primary progressive multiple sclerosis. Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is effective in relapse-onset multiple sclerosis, but has not been assessed in primary progressive multiple sclerosis. We assessed the safety and efficacy of fingolimod in patients with primary progressive multiple sclerosis.
Original languageEnglish
Pages (from-to)1075-1084
JournalLancet
Volume387
Issue number10023
DOIs
Publication statusPublished - 12 Mar 2016

Cite this